Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC)
Patients with mRCC being considered for clinical trial enrollment.
In chart reviews the MKCC/Motzer score retrospectively placed clinical trial subjects from the 1970s-1990s with metastatic renal cell carcinoma (mRCC) into three groups: poor, intermediate, and favorable survival. There are no successful validations (later studies confirmed some predictors but not others), and the score has not been applied successfully to patients in common practice or those receiving modern targeted therapies such as sunitinib.
- Most widely used prognostic algorithm for metastatic RCC.
- Originally created in 1999, new inputs were added in 2002 (treatment with interferon alpha) and 2004 (previously failed cytokine therapy).
- Validated in multiple patient cohorts. Externally validated at the Cleveland Clinic.
- Limitations: only for metastatic RCC.
There are no validated scoring systems for predicting survival in mRCC. Using a score may help sketch categories of survival time better than clinical judgment alone.
Please fill out required fields.
The Motzer score is often used for mRCC, commonly for selecting patients to enroll in clinical trials. The score retrospectively identified some variables associated with survival, which may ultimately help predict outcomes.
We are unaware of validated management algorithms using the score.
The Motzer score is not known to be accurate for individual survival prediction and should be considered a general guide rather than a reliable predictor.
Addition of selected points, as above.
Facts & Figures
|1 - 2||Intermediate||10 months|
Original/Primary ReferenceTsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000 Apr;163(4):1090-5; quiz 1295.
ValidationMotzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999 Aug;17(8):2530-40.
About the Creator
Robert J. Motzer, MD, is a medical oncologist at Memorial Sloan Kettering Cancer Center. He received the Career Development Award from the National Institutes of Health and the Schonfeld Award from the Kidney Cancer Association. Dr. Motzer’s research focuses on renal cell carcinoma, germ-cell tumors, and bone marrow and blood cell transplantation.
To view Dr. Robert J. Motzer's publications, visit PubMed